The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

spherics.com

Founded Year

1997

Stage

Series C | Alive

Total Raised

$40.48M

Last Raised

$26.4M | 17 yrs ago

About Spherics

Pharmaceutical company focused on applying its oral drug delivery platform to develop products with improved therapeutic profiles

Spherics Headquarter Location

375 Forbes Boulevard

Mansfield, Massachusetts, 02048,

United States

508-452-7000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Spherics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Spherics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

  • When was Spherics founded?

    Spherics was founded in 1997.

  • Where is Spherics's headquarters?

    Spherics's headquarters is located at 375 Forbes Boulevard, Mansfield.

  • What is Spherics's latest funding round?

    Spherics's latest funding round is Series C.

  • How much did Spherics raise?

    Spherics raised a total of $40.48M.

  • Who are the investors of Spherics?

    Investors of Spherics include CB Health Ventures, Zero Stage Capital, Pod Investment, Eastman, BPEA Private Equity and 8 more.

  • Who are Spherics's competitors?

    Competitors of Spherics include Chiasma, Sagent Pharmaceuticals, Catalent, Quinnova Pharmaceuticals, Glide Pharma and 12 more.

You May Also Like

K
Kucera Pharmaceutical Company

Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.

M
MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products.

G
Glide Pharma

Glide Pharma, formerly Caretek Medical, is a specialty pharmaceutical company developing products for easy, safe and convenient delivery of pharmaceuticals and vaccines using its Glide SDI - the Solid Dose Injector. By being much less invasive than traditional injection methods, Glide improves the treatment experience of both patients and carers and, by allowing the injection of solid formulations, opens up a wide range of therapeutic options for new and existing treatments.

M
MedManage Systems

MedManage Systems, Inc. aims to provide drug sampling solutions. The company's OmniSampleSM Solution aims to allow pharmaceutical companies to intensify physician use of trial medications, thereby increasing product revenues.

F
FORMAC Pharmaceuticals N.V.

FORMAC is a pharmaceutical R&D company engaged in drug delivery and development. The firm aims to increase pharmaceutical R&D productivity and product value by enhancing the performance of (pre)clinical drug candidates and marketed drugs.

T
Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.